Stanpack Pharma Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 12-07-2024
- Paid Up Capital ₹ 4.00 M
as on 12-07-2024
- Company Age 30 Year, 9 Months
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 1.84 Cr
as on 12-07-2024
- Satisfied Charges ₹ 23.88 Cr
as on 12-07-2024
- Revenue 101.00%
(FY 2018)
- Profit 107.58%
(FY 2018)
- Ebitda 76.19%
(FY 2018)
- Net Worth 0.58%
(FY 2018)
- Total Assets 0.19%
(FY 2018)
About Stanpack Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 4.00 M.
The company currently has active open charges totaling ₹1.84 Cr. The company has closed loans amounting to ₹23.88 Cr, as per Ministry of Corporate Affairs (MCA) records.
Archana Prasad and Sanjay Prasad serve as directors at the Company.
- CIN/LLPIN
U24239MH1994PTC077217
- Company No.
077217
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Mar 1994
- Date of AGM
28 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Stanpack Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Prasad  | Managing Director | 22-Mar-1994 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Archana Prasad | Director | 01-Apr-2009 | Current |
Financial Performance of Stanpack Pharma.
Stanpack Pharma Private Limited, for the financial year ended 2018, experienced significant growth in revenue, with a 101% increase. The company also saw a substantial improvement in profitability, with a 107.58% increase in profit. The company's net worth moved up by a moderate rise of 0.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stanpack Pharma?
In 2018, Stanpack Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Tifac Creation Date: 24 Nov 2008 | ₹1.84 Cr | Open |
Union Bank Of India Creation Date: 14 Mar 2011 | ₹3.85 Cr | Satisfied |
Union Bank Of India Creation Date: 04 Jun 2007 | ₹1.00 Cr | Satisfied |
How Many Employees Work at Stanpack Pharma?
Unlock and access historical data on people associated with Stanpack Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stanpack Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stanpack Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
